# Relmada Therapeutics (RLMD) — Earnings

RLMD · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/rlmd/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.11 |
| EPS estimate | −$0.20 |
| EPS surprise | +44.86% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1553643/000121390026086151/ea0298199-10q_relmada.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/b44a2a29-e940-4ec8-5cbe-04eff2e834c9.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | −$0.20 | −$0.11 | 44.86% | — | — |
| Q1 2026 | May 12, 2026 | −$0.20 | −$0.22 | -9.84% | — | — |
| Q4 2025 | Mar 19, 2026 | −$0.15 | −$0.27 | -81.70% | — | — |
| Q3 2025 | Nov 13, 2025 | −$0.42 | −$0.30 | 29.28% | — | — |
| Q2 2025 | Aug 7, 2025 | −$0.46 | −$0.30 | 34.78% | — | — |
| Q1 2025 | May 12, 2025 | −$0.48 | −$0.58 | -20.83% | — | — |
| Q4 2024 | Mar 27, 2025 | −$0.67 | −$0.62 | 7.92% | — | — |
| Q3 2024 | Nov 7, 2024 | −$0.68 | −$0.72 | -6.67% | — | — |
| Q2 2024 | Aug 7, 2024 | −$0.83 | −$0.59 | 28.70% | — | — |
| Q1 2024 | May 8, 2024 | −$0.85 | −$0.72 | 15.29% | — | — |
| Q4 2023 | Mar 19, 2024 | −$0.83 | −$0.84 | -1.20% | — | — |
| Q3 2023 | Nov 8, 2023 | −$0.91 | −$0.73 | 20.13% | — | — |
| Q2 2023 | Aug 8, 2023 | −$0.90 | −$0.84 | 6.15% | — | — |
| Q1 2023 | May 11, 2023 | −$0.89 | −$0.87 | 2.25% | — | — |
| Q4 2022 | Mar 23, 2023 | −$1.33 | −$1.28 | 3.64% | — | — |
| Q3 2022 | Nov 10, 2022 | −$1.45 | −$1.31 | 9.66% | — | — |
| Q2 2022 | Aug 11, 2022 | −$1.27 | −$1.33 | -4.49% | — | — |
| Q1 2022 | May 5, 2022 | −$1.27 | −$1.40 | -10.61% | — | — |
| Q4 2021 | Mar 23, 2022 | −$1.83 | −$1.80 | 1.64% | — | — |
| Q3 2021 | Nov 12, 2021 | −$1.60 | −$2.44 | -52.82% | — | — |

## Frequently Asked Questions

### When did Relmada Therapeutics (RLMD) last report earnings?

Relmada Therapeutics last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did RLMD beat earnings estimates?

Yes. Relmada Therapeutics reported EPS of −$0.11 for Q2 2026 against a −$0.20 estimate — a 44.86% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).